Dr Aurora Pujol received her MD from the Autonomous University of Barcelona in 1993 and her PhD in Cell and Molecular Biology from the University of Heidelberg/ German Cancer Research Center in 1998. She trained in Human Genetics with Prof JL Mandel at the IGBMC, Strasbourg, generating and characterizing mouse models for a rare neurometabolic disorder, adrenoleukodystrophy (X-ALD), combined with diagnostic activities as Medical Geneticist at the Louis Pasteur Hospital. In 2005, she became ICREA Professor and Director of the Neurometabolic Diseases Lab at IDIBELL. In 2017 she obtained the specialty in Clinical Genomics by the American Board ABMGG, at the NIH, USA. Her lab is a member of the Spanish Network of Rare Diseases CIBERER, and of the Undiagnosed Diseases International Network of NIH (UDNI), USA. Dr Pujol serves at the Neurobiology of Disease and J of Neuroscience Research Editorial Boards.
Our mission is to improve disease management of rare brain disorders through precision medicine. This spans the whole spectrum from genomic diagnosis to disease-modifying treatments. A first research line revolves around adrenoleukodystrophy (ALD), made popular by the movie “Lorenzo’s Oil”. We are integrating multiomic approaches to gain insights into pathomechanisms and for drug target identification. These involve redox and metabolic homeostasis, mitochondria dynamics, proteostasis and cellular stress responses. Tailored preclinical tests have yielded four licensed patents, three phase II/III clinical trials, and two Orphan Drug Designations. A second research line applies clinical and functional genomics for diagnostics and gene discovery. We are identifying novel disease-causing genes and modeling disease using iPS-derived brain organoid cultures and zebrafish. Results are advancing scientific knowledge while serving the undiagnosed patient’s community.
– Pant DC, (42 more coauthors) & Pujol A 2019, ‘Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy‘, Journal Of Clinical Investigation, vol.129, no. 3, pp 1240-1256.
– Casasnovas C, (16 more coauthors) & Pujol A 2019, “Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study“, Neurotherapeutics, 16(4):1167-1182
– Casasnovas C, Verdura E, Vélez V, Schlüter A, Pons-Escoda A, Homedes C, Ruiz M, Fourcade S, Launay N & Pujol A 2019, ‘A novel mutation in the GFAP gene expands the phenotype of Alexander disease‘, Journal Of Medical Genetics, vol. 56, no. 12, pp 846-849.
– De la Casa-Fages B, (24 more coauthors), Pujol A & López de Munain A 2019, ‘Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism‘, Movement Disorders, vol. 34, no. 10, pp 1547-1561.
– De la Casa-Fages B, (24 more coauthors), Pujol A & López de Munaín A 2019, “Reply to: “Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion”, Movement Disorders, vol. 34, no.12, pp. 1932-1933
– Rattay TW, (27 more coauthors), Pujol A & Schüle R 2019, ‘FAHN/SPG35: a narrow phenotypic spectrum across disease classifications‘, Brain, vol. 142, no. 6, pp 1561-1572.
– Gu S; (14 more coauthors), Pujol A & Meng L 2019, ‘Truncating variants in UBAP1 associated with childhood-onset nonsyndromic hereditary spastic paraplegia‘, Human Mutation, 2019 Nov 7. doi: 10.1002/humu.23950.
Selected research activities
– Late breaking news Award, 2019 Annual Symposium of the Society for the Study of Inborn Errors in Metabolism (SSIEM), 3 – 6 September, Rotterdam, The Netherlands.
– Albus Award, Grifols Scientific Awards, 2019.